Loading
Life sciences · Journal article
Scientific Reports · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Non-small cell lung cancer (NSCLC) harboring KRAS G12D mutations and TP53 deficiency is associated with poor clinical outcomes, and effective therapeutic options remain limited. Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have made tremendous advances in lung cancer therapy over the last few years. Despite this, only a subset of patients receives durable clinical responses with PD-1/PD-L1 monotherapy. Tumor-associated macrophages (TAMs), especially M2 macrophages, play a critical role in shaping the immunosuppressive tumor microenvironment (TME) and in resistance to PD-L1 blockade. In this study, we utilized an interleukin-4 receptor (IL-4R)-binding peptide conjugated to the pro-apoptotic peptide (KLAKLAK)₂ (IL4RPep-1-KLA) to induce apoptosis in IL4R-expressing M2 macrophages. We found that both anti-PD-L1 antibody and IL4RPep-1-KLA monotherapy exhibited antitumor effect in NSCLC-bearing mice. Although co-administration of these two agents did not show a significant survival benefit, the combination markedly enhanced the infiltration of CD8 + T cells and granzyme B + cells within the tumor core, promoted systemic CD8⁺ T cell activation in the periphery and reduced the proportion of M2 macrophages in the TME. Thus, targeting M2 macrophages may provide a novel approach to remodel the immunosuppressive TME and potentially contribute to developing a new therapeutic modality that can address limitations of PD-L1-based therapies.